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Abstract  Chikungunya  virus  (CHIKV)  is  a  re-emerging  mosquito  borne  alphavirus  responsible
for the  recent  outbreak  in  the  Americas.  Immunologically  naïve  population  in  the  Americas
favors the  spread  of  epidemics.  Chikungunya  fever  is  characterized  by  an  abrupt  febrile  illness,
polyarthralgia  and  maculopapular  rash.  In  chikungunya  fever,  shock  or  severe  hemorrhage  is
very rarely  observed;  the  onset  is  more  acute  and  the  duration  of  fever  is  shorter  than  dengue
disease.  The  pain  is  much  more  pronounced  and  localized  to  the  joints  and  tendons  in  chikun-
gunya fever,  in  comparison  to  dengue  fever.  There  is  no  speciﬁc  and  effective  antiviral  therapy
and vaccines  are  still  in  trails.  The  only  effective  preventive  measures  consist  of  individual  pro-
tection against  mosquito  bites  and  vector  control.  Disease  prevention  is  important  due  to  the
economic  burden  it  entails.  Clinicians  need  to  distinguish  chikungunya  fever  between  dengue
fever and  other  diseases  to  give  a  successful  treatment  and  prevent  disease  spreading.
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hikungunya  fever  is  a  viral  disease  transmitted  through  the
ite  of  infected  Aedes  mosquitoes.  The  disease  typically
onsists  of  an  acute  illness  with  fever,  skin  rash,  and  incapac-
tating  arthralgia.  The  word  chikungunya  means,  ‘‘to  walk
ent  over’’  in  the  African  dialect  Makonde,  and  refers  to  the
ffect  of  the  incapacitating  arthralgia  seen  in  the  affected
asson Doyma México S.A. This is an open access article under the
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atients.1 Chikungunya  virus  (CHIKV)  is  the  etiological  agent
nd  a  member  of  the  Alphavirus  genus  in  the  Togaviridae
amily.2
Chikungunya  cases  occur  in  Africa,  Asia  and  the  Indian
ubcontinent.  Human  infections  in  Africa  have  been  at  rel-
tively  low  levels  for  a  number  of  years.  In  December  2013,
rance  reported  2  laboratory-conﬁrmed  autochthonous
ases  of  in  the  French  part  of  the  Caribbean  island  of  St
artin.  Since  then,  local  transmission  has  been  conﬁrmed  in
ver  43  countries  and  territories  in  the  American  region.3
his  was  the  ﬁrst  documented  outbreak  of  CHIKV  with
utochthonous  transmission  in  the  Americas;  therefore  it  is
ubject  of  big  concern  in  our  continent.
HIKV genome, structure and replication
hikungunya  virus  is  an  enveloped  plus-strand  RNA  virus  with
cosahedral  symmetry.  The  virion  is  70  nm  in  diameter  and  it
s  composed  of  repeating  units  of  the  E1  and  E2  transmem-
rane  glycoproteins  (240  heterodimers  of  E2/E1  arranged  as
rimeric  spikes  on  its  surface),  the  capsid  (C),  a  host-derived
ipid  bilayer,  and  a  single  molecule  of  genome  RNA.4 The
enome  is  approximately  12  kb  in  length  and  encodes  the
onstructural  proteins  (nsPs)  at  the  5′ end  and  the  struc-
ural  proteins  at  the  3′ end.  The  nsPs  are  translated  from
enomic  RNA  and  the  structural  proteins  from  a  subgenomic
NA  (Fig.  1).5
Alphaviruses  enter  target  cells  by  endocytosis.  A  few
eceptors  (DC-SIGN,  L-SIGN,  heparin  sulphate,  laminin  and
ntegrins)  have  been  implicated  in  this  process,  but  their
recise  roles  have  not  been  clearly  proven.5 Recently,
rohibitin  was  identiﬁed  as  CHIKV  receptor  protein.6 Fol-
owing  endocytosis,  the  acidic  environment  of  the  endosome
riggers  conformational  changes  in  the  viral  envelope  that
xpose  the  E1  peptide,  which  mediates  virus--host  cell  mem-
rane  fusion.  This  allows  cytoplasmic  delivery  of  the  core
nd  release  of  the  viral  genome.  Two  precursors  of  non-
tructural  proteins  are  translated  from  the  viral  mRNA,
nd  cleavage  of  these  precursors  generates  nsP1--nsP4.7
hese  proteins  assemble  to  form  the  viral  replication  com-
lex,  which  synthesizes  a  full-length  negative-strand  RNA
ntermediate.  This  serves  as  the  template  for  the  synthe-
is  of  both  subgenomic  (26S)  and  genomic  (49S)  RNAs.  The
ubgenomic  RNA  drives  the  expression  of  the  C--pE2--6K--E1
olyprotein  precursor,  which  is  processed  by  autoprotoly-
is.  The  capsid  is  released,  and  further  processing  generates
he  pE2  and  E1  glycoproteins.  PreE2  and  E1  associate  in  the
olgi  and  are  exported  to  the  plasma  membrane,  where  pE2
s  cleaved  into  E2  and  E3.  Binding  of  the  viral  nucleocapsid
o  the  viral  RNA  and  the  recruitment  of  the  membrane-
ssociated  envelope  glycoproteins  promote  viral  assembly.
he  assembled  alphavirus  particle,  with  an  icosahedral  core,
uds  at  the  cell  membrane.5,7
ectors, transmission and reservoirs
wo  distinct  transmission  cycles  have  been  well  docu-
ented:  enzootic  and  urban.  In  Africa,  an  enzootic  cycle
ccurs  in  forested  habitats  where  arboreal  mosquitoes,
rincipally  Aedes  spp,  serve  as  vectors.  Evidence  points
o  nonhuman  primates  as  the  principal  reservoir  and
i
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mpliﬁcation  hosts  in  the  enzootic  cycle  based  on  their  high
ates  of  seroprevalence,  documented  infection  and  viremia
n  nature,  and  viremia  levels  in  response  to  experimental
nfection.8
The  enzootic  transmission  cycle  can  spill  over  to  infect
eople  who  live  nearby,  and  enzootic  mosquito  vectors
ay  be  involved  in  interhuman  transmission  during  small
utbreaks.  Epidemics  also  occur  in  Africa  when  CHIKV  is
ntroduced  into  urban  areas  where  the  more  anthropophilic
ectors,  Aedes  aegypti  and  Aedes  albopictus,  can  initiate
uman--mosquito--human  transmission.
CHIKV  is  capable  of  initiating  a  sustained,  urban  transmis-
ion  cycle  that  relies  only  on  A.  aegypti  and/or  A.  albopictus
nd  human  ampliﬁcation  hosts.9 This  endemic/epidemic
ycle  results  in  high  levels  of  human  exposure  to  mosquito
ransmission,  particularly  because  these  vectors  live  in  close
roximity  to  people.
The  behavior  and  ecology  of  A.  aegypti,  in  particular,  are
deal  for  epidemic  transmission  because  adult  females  pre-
er  to  feed  on  humans,  often  take  several  partial  blood  meals
uring  a  single  gonotrophic  cycle,  oviposit  in  artiﬁcial  con-
ainers  as  their  preferred  larval  sites,  and  rest  inside  houses
ith  ready  access  to  human  hosts.10
A.  albopictus  is  both  zoophilic  and  anthropophilic,
ggressive,  silent,  active  all-day  long,  and  has  a  longer
ifespan  than  other  mosquitoes  (up  to  8  weeks).  In  recent
ecades  it  has  expanded  to  several  areas  previously  known
o  be  Aedes-free.11,12 It  seems  that  most  new  introductions
f  A.  albopictus  have  been  caused  by  vegetative  eggs  con-
ained  in  timber  and  tires  exported  from  Asia  throughout  the
orld.13
Although  the  infectivity  of  various  CHIKV  strains  varies
idely  for  both  A.  aegypti  and  A.  albopictus, humans
evelop  high-titer  viremias  that  generally  persist  during
he  ﬁrst  4  days  after  the  onset  of  symptoms,  with  the
eak  estimated  on  the  day  of  onset  at  approximately
09 viral  RNA  copies/ml14 and  infectious  titers  sometimes
xceeding  107 PFU/ml.15 These  titers  generally  exceed  the
ral  infectious  dose  50%  levels  for  both  epidemic  vector
pecies,  permitting  efﬁcient  transmission  among  humans  by
osquitoes.16
Human  beings  serve  as  the  main  CHIKV  reservoir  during
pidemic  periods.  Outside  these  periods,  monkeys,  rodents,
nd  birds  constitute  the  virus  reservoir  sustaining  virus  circu-
ation  in  the  environment  in  the  absence  of  human  cases.17,18
eographic distribution
HIKV  is  typically  found  being  transmitted  in  Africa  and
outheast  Asia.  Since  its  discovery  in  1952,  CHIKV  has  caused
everal  epidemics  in  these  places.19,20
The  last  huge  outbreak  started  in  Kenya  in  2004  and
pread  through  neighbor  islands  to  La  Réunion  in  2005.21
fter  that,  the  virus  spread  to  several  islands  in  the  Indian
cean  and  India.1,22 From  India  it  spread  to  Sri  Lanka,  Thai-
and,  Malaysia  and  ﬁnally  to  Italy  in  2007.23,24 In 2009  CHIKV
ransmission  restarted  in  La  Réunion  and  lead  to  CHIKV  re-
mportation  to  Europe  in  May  2010.25
During  2011,  CHIKV  was  transmitted  in  Oceania,  Central
frica,  Southern  and  Southeastern  Asia,  Europe  and  West-
rn  Indian  Ocean  Islands.  In  2012,  CHIKV  was  reported  in:
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Figure  1  Organization  of  the  chikungunya  virus  genome.  The  ﬁgure  shows  the  nonstructural  and  structural  proteins  the  way  they
are organized  throughout  the  genome  as  well  as  the  non-translatable  regions  in  5′ and  3′.  The  function  and  size  in  amino  acids
is showed  for  each  protein.  The  ﬁgure  is  drawn  to  scale  based  on  the  CHIKV  genome  with  GenBank  access  number:  AM258990.
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eThe non-translatable  regions  sizes  were  obtained  from  Hyde  e
nonstructural  protein;  C,  capsid;  E,  envelope;  AA,  amino  acid.
Southeastern,  Southern  and  Western  Asia;  Oceania;  Central
and  Western  Africa;  and  Western  Indian  Ocean  Islands.  Dur-
ing  2013,  CHIKV  was  transmitted  in  Southeastern,  Southern
and  Eastern  Asia  and  Oceania.20
The  current  outbreak  started  in,  the  Caribbean  Island,
Saint  Martin  on  December  6,  2013.26 During  December
2013  and  January  2014  it  spread  to  the  neighbor  islands.27
In  February,  it  continued  spreading  and  reached  French
Guiana.28 In  May,  Guiana  and  almost  all  the  Caribbean
Islands  reported  autochthonous  CHIKV  infections.29 In  June,
the  ﬁrst  cases  of  El  Salvador  were  reported.30 By  July,
autochthonous  transmission  was  reported  in  Florida,  USA,
Costa  Rica,  Panama  and  Venezuela.31 By  September,  cases
were  reported  in  Guatemala,  Colombia  and  Brazil.32 In  Octo-
ber,  Nicaragua  and  Paraguay  reported  cases  for  the  ﬁrst
time  and  Guatemalan  cases  rose.33 By  the  end  of  Novem-
ber,  Mexico  reported  its  ﬁrst  autochthonous  transmission  in
the  southern  state  of  Chiapas.  Also  by  this  month,  Belize  and
Honduras  reported  cases.34
According  to  the  Pan  American  Health  Organization
(PAHO),  since  the  current  outbreak  started,  there  have  been
1,280,953  suspected  autochthonous  transmission  cases  and
more  than  26,300  have  been  conﬁrmed  in  America.35 The
recent  reports  obtained  from  Mexico  reveals  405  conﬁrmed
autochthonous  transmissions.35 Nevertheless,  this  numbers
does  not  include  patients  that  did  not  look  for  medical  aid.
Phylogeny
There  are  four  identiﬁed  CHIKV  lineages,  each  with  dis-
tinct  genotypic  and  antigenic  characteristics.  The  ﬁrst
phylogenetic  study  revealed  that  CHIKV  spread  from  Africa
where  two  major  lineages  circulated:  West  African  and
East/Central/South  African  (ECSA).  Posteriorly  the  ECSA  lin-
eage  spread  to  Asia  and  originated  the  Asian  lineage.36,37
Until  2004,  these  were  the  only  identiﬁed  CHIKV  lineages
that  were  circulating.  The  source  of  the  2005  Indian  Ocean
epidemic  was  traced  to  the  ECSA  lineage.38 When  the  Indian
Ocean  epidemic  started  in  Kenya  2004,  the  ﬁrst  CHIKV  iso-
lates  from  La  Réunion  epidemic  exhibited  an  alanine  at  E1
envelope  protein  residue  226,  but  later  isolates  showed  an
A226V  substitution.  This  and  additional  substitutions  gave
rise  to  the  fourth  lineage,  Indian  Ocean  lineage.38,39
r
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f92 The  ﬁgure  was  adapted  from  Weaver61 and  Solignat.93 nsP,
athogenesis
he  pathogenesis  of  CHIKV  infection  in  humans  is  still
oorly  understood,  but  recent  outbreaks  have  helped
roviding  insights  into  the  cells  and  organs  involved  in
iral  replication.  Following  intradermal  inoculation  by
nfected  mosquitoes,  CHIKV  directly  enters  the  subcu-
aneous  capillaries  and  infects  susceptible  cells  in  the
kin:  macrophages,  ﬁbroblasts  and  endothelial  cells,  where
imited  replication  occurs.40 Locally  produced  viruses  are
ransported  to  secondary  lymphoid  organs,  where  it  infects
igratory  cells  and  release  viruses  to  the  lymph  circula-
ion  and  proceed  to  blood.20 Once  in  the  blood,  the  virus
as  access  to  various  parts  of  the  body,  including  the  liver,
uscle,  joints  and  brain.41 In  these  tissues,  the  infection  is
ssociated  with  a marked  inﬁltration  of  mononuclear  cells.
he  mononuclear  cell  inﬁltration  and  viral  replication  in
uscles  and  joints  are  associated  with  pain.42,43
CHIKV  infection  elicits  strong  systemic  innate  responses,
rincipally  involving  the  production  of  antiviral  IFN- as
ell  as  many  pro-inﬂammatory  cytokines,  chemokines,  and
rowth  factors.44 This  is  followed  by  the  activation  of  the
daptive  immunity  through  activation  and  proliferation  of
D8+ T  cells  in  the  early  stages  of  the  disease.  A  classical
witch  to  CD4+ T-cell  response  and  the  production  of  anti-
nﬂammatory  proteins  IL-1RA  and  IL-2RA  are  characteristics
f  later  stages  of  the  acute  phase.44
CHIKV  infection  induces  a  strong  inﬂammatory  response
hat  is  possibly  orchestrated  by  the  production  of  IL-16,
L-17,  monocyte  chemoattractant  protein  1  (MCP-1),  IP-10,
nd  MIP-1. The  end  of  the  acute  phase  is  characterized
y  the  production  of  proinﬂammatory  MIF,  MIP-1, SDF-
,  and  IL-6  and  IL-8.  CCL5  (RANTES)  levels  were  also
igh  in  all  patients  during  the  ﬁrst  week  after  symptom
nset.44 CCL5,  MCP-1,  IP-10,  MIP-1, and  IL-8  are  produced
y  activated  macrophages  that  are  susceptible  to  CHIKV
nfection.40 These  chemokines  play  a  major  role  in  leukocyte
ecruit  to  sites  of  infection,  coordinating  the  deployment  of
fﬁcient  antiviral  defenses.
CHIKV  infection  also  induces  strong  cellular  immune
esponse.  High  plasma  levels  of  IFN-, IL-4,  IL-7,  and  IL-
2p40,  cytokines  that  promote  the  adaptive  immunity,
uggested  the  involvement  of  cellular  responses.44A  key  role
or  natural  killer  cells  in  the  clearance  of  infected  cells
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nd  in  the  development  of  CHIKV  arthralgia  has  also  been
uggested.45 The  B  cell-promoting  cytokines  IL-4  and  in  some
ases  IL-10,  were  also  up  regulated  in  the  ﬁrst  few  days
fter  symptom  onset  probably  initiating  the  production  of
HIKV-speciﬁc  IgG.  Additionally,  CD4+ T  lymphocytes,  which
re  also  involved  in  the  promotion  of  humoral  responses,
ere  strongly  activated  toward  the  end  of  the  acute
hase.44
IgG  antibodies  are  detected  in  the  ﬁrst  week  after
nfection,  indicating  rapid  seroconversion  and  high  levels
f  antibody  responses  among  CHIKV-infected  individuals.46
peciﬁc  IgM  lasts  for  3--4  months  from  the  onset  of  the  dis-
ase,  and  that  IgG  lasts  more  than  6  months.47 However,
heir  role  in  chronic  arthralgia  is  not  very  well  understood.
linical manifestations
hikungunya  fever  is  characterized  by  an  abrupt  febrile  ill-
ess,  polyarthralgia  and  maculopapular  rash.  The  incubation
eriod  lasts  2--4  days  (rage  1--12  days)  and  asymptomatic
nfections  occur  in  5--15%  of  the  cases.48
Studies  conducted  in  infected  patients  during  La  Réunion
utbreak  indicated  that  arthralgia  was  bilateral  and  sym-
etrical  in  78.4%  of  the  patients.  It  affected  mostly  ankles,
nees,  hands,  wrists,  feet,  shoulders,  and  elbows.49--52 Rash
as  present  in  54%  of  the  patients,  predominantly  on  the
runk  and  arms.  Periarticular  edema  was  reported  in  45%
f  the  patients,  affecting  the  ankles  in  a  greater  propor-
ion.  Myalgia  and  headache  were  present  in  72  and  63%  of
he  patients,  respectively.  Hemorrhagic  signs  such  as  gin-
ivorrhagia  and  epistaxis  were  only  present  in  10.6%  of  the
atients.49--52
Radiological  ﬁndings  are  normal  and  biological  mark-
rs  of  inﬂammation  like  erythrocyte  sedimentation  rate
nd  C-reactive  protein  are  moderately  elevated.49,50,52--54
ridocyclitis  and  retinitis  are  the  most  common  ocular  man-
festations  associated  with  CHIKV  infection  and  have  a
enign  course  with  complete  resolution  and  preservation  of
ision.55
The  acute  signs  and  symptoms  usually  resolve  in  less
han  2  weeks,  but  arthralgia  may  last  for  weeks,  months
r  even  years;56,57 this  is  a  clinical  symptom  that  may  distin-
uish  CHIKV  from  dengue  virus  infection.  Also  in  a  univariate
nalysis,  CHIKV  infected  patients  displayed  fewer  gastroin-
estinal  symptoms  compared  to  dengue-infected  patients,
nd  a  higher  proportion  of  myalgia  and  arthralgia.58
Chikungunya  is  not  generally  considered  life  threaten-
ng;  nevertheless  severe  forms  can  also  be  present.  Patients
ith  severe  chikungunya  fever  requiring  hospitalization  tend
o  be  older  and  have  comorbidities  such  as  cardiovascu-
ar,  neurologic,  and  respiratory  disorders  or  diabetes,  which
re  independent  risk  factors  for  severe  disease.49,59 Severe
hikungunya  can  manifest  as  encephalopathy  and  encephali-
is,  myocarditis,  hepatitis,  and  multiorgan  failure.  These
are  forms  can  be  fatal  and  typically  arise  in  patients  with
nderlying  medical  conditions.60,61 Neonates  are  also  at  risk
or  severe  infection  associated  with  neurologic  signs.  The
ate  of  infection  of  neonates  born  to  viremic  mothers  and
xposed  to  the  virus  during  birth  can  reach  50%,  leading  to
evere  disease  and  encephalopathy,  resulting  in  long-term
eurological  sequelae  and  poor  outcome.62
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In  general,  CHIKV  infection  has  a  good  prognosis.  Nev-
rtheless,  older  patients  (<45  years  old)  are  more  likely
o  evolve  toward  relapsing  and  lingering  chronic  rheumatic
usculoskeletal  pain.63 A  study  showed  that  subjects  who
xperienced  severe  initial  rheumatic  involvement  (six  or
ore  painful  sites  with  at  least  four  other  symptoms)  at  the
cute  stage  of  infection  were  more  likely  to  exhibit  chronic
heumatic  musculoskeletal  pain  on  follow  up.63 Moreover,
 positive  association  between  high  titers  of  CHIKV-speciﬁc
gG  in  the  plateau  phase  and  long-lasting  arthralgia  has  been
bserved  contemporaneously  from  a  pilot  study  and  in  the
talian  cohort.63,64 A  possible  mechanistic  hypothesis  may  be
hat  an  imbalance  toward  B  cell  expansion  and  differentia-
ion,  in  response  to  IL-6  secretion  following  the  progression
f  both  immunosenescence65 and  chikungunya  is  triggered
y  viral  persistence  in  host  sanctuaries.66,67
Taking  in  consideration  the  clinical  features  mentioned
bove,  the  algorithm  presented  in  Fig.  2  would  guide  the
linician  throughout  case  deﬁnition,  and  management.  This
lgorithm  is  an  adaptation  from  Palacios-Martinez.68
iagnosis
hikungunya  infection  is  diagnosed  on  the  basis  of  clini-
al,  epidemiological  and  laboratory  criteria.  An  acute  onset
f  fever  and  severe  arthralgia  or  arthritis  that  is  not
xplained  by  other  medical  disorders  is  considered  a  pos-
ible  CHIKV  case.20Three  main  types  of  laboratory  tests
re  used  for  diagnosing  CHIKV  infection:  virus  isolation,
everse  transcriptase-polymerase  chain  reaction  (RT-PCR),
nd  serology.
Virus  isolation  can  be  performed  on  ﬁeld  collected
osquitoes  or  acute  serum  specimens  (≤8  days).  Serum
btained  from  whole  blood  collected  during  the  ﬁrst  week  of
llness  can  be  inoculated  into  a  susceptible  cell  line  or  suck-
ing  mouse  at  a  reference  laboratory.  This  can  be  achieved
f  the  sample  is  transported  cold  (between  2 ◦C  and  8 ◦C  or
ry  ice)  and  as  soon  as  possible  (within  48  h).69
Several  RT-PCR  assays  for  the  detection  of  CHIKV  RNA
ave  been  published.  Real-time,  closed  system  assays  should
e  used,  due  to  their  increased  sensitivity  and  lower  risk
f  contamination.  Taking  into  account  the  sensitivity,  PAHO
ecommends  the  use  of  the  CHIKV  RT-PCR  protocols  from  the
enters  for  Disease  Control  and  Prevention  and  the  Institute
asteur.14,70 Serum  from  whole  blood  is  used  for  PCR  testing
s  well  as  virus  isolation.
For  serological  diagnosis,  serum  obtained  from  whole
lood  is  used  in  enzyme-linked  immunosorbent  assay
ELISA).  The  serum  (or  blood)  specimen  should  be  trans-
orted  at  2--8 ◦C  and  should  not  be  frozen.  Serologic
iagnosis  can  be  made  by  demonstration  of  IgM  antibodies
peciﬁc  for  CHIKV  or  by  a  four-fold  rise  in  IgG  titer  in  acute
nd  convalescent  specimens.69
The  determination  of  IgM  can  be  made  by  different  com-
ercially  available  techniques.  However,  it  should  be  taken
nto  account  that  the  best  sensitivity  is  from  techniques  that
se  the  complete  virus  as  antigen  compared  to  those  that  use
ecombinant  proteins.  Since  the  ﬁrst  commercially  available
its  had  poor  results,  it  is  recommended  that  in  house  tech-
iques  for  IgM/IgG  ELISA  be  implemented  using  the  puriﬁed
iral  antigen  and  following  the  CDC  protocols.60 Recent  ELISA
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Clinical criteria
Acute onset of fever
> 38,5°C and severe
arthralgia/arthritis not
explained by other
medical conditions.
Residing or having visited
epidemic areas, having
reported transmission within
15 days prior to the onset of
symptoms.
Epidemiological criteria
Viral isolation
Presence of viral ARN
Presence of specific lgM/lgG
antibodies
Four fold increase of antibodies in
two samples separated by 14 days.
Laboratory criteria
•
•
•
•
CHIKV fever clinical suspicion
Emergency department admission
Vital signs measurement hourly
Supportive treatment
•
•
Hospital care
Yes
Yes
No
Asses
No
NoYesTransfer to third
level hospital
Atypical
manifestations or
severity signs
Dengue or malaria
warning signs
Hemodynamic instability
Postural dizziness, cold
extremities
Decreased urine output
Any bleeding under the skin or
through any orifice
Incessant vomiting
Pregnancy
Patients above 60 years old or
newborns
•
•
•
•
•
•
•
Symptomatic treatment:
Acetaminophen until other etiologies, like
dengue, are ruled out.
•
Non-steroidal anti-inflammatory drugs or
narcotics can be used if acetaminophen
does not provide relief.
•
Observation•
Asses evolution•
Observation•
Asses evolution•
Hemodynamic status and hydration•
Renal failure, neurologic alterations,
hepatic failure
•
Suspected case
Clinical criteria: +
Epidemiological criteria: +
Laboratory criteria: -
Primary attention or
ambulatory care
Immediate notification
to ministry of health
Confirmed case
Clinical criteria: +
Epidemiological criteria: +/-
Laboratory criteria: +
Figure  2  CHIKV  infection  diagnostic  and  therapeutic  algorithm.
Adapted  from  Palacios-Martinez.63
Table  1  Accuracies  and  sensitivities  of  different  chikungunya  fever  diagnostic  assays.
Assay  Sensibility  (%)  Speciﬁcity  (%)  PPV  (%)  NPV  (%)
RT-PCR  88.5  100  100  97.5
Standard Diagnostics  Chikungunya  IgM  ELISA  3.9  92.5  10  81.6
Novatech Chikungunya  IgM  Capture  ELISA  76.9  91.9  100  97.5
Novatech Chikungunya  IgG  Capture  ELISA  80  100  100  95.6
Source:  Modiﬁed and adapted from Blacksell.71,89--91
PPV, positive predictive value; NPV, negative predictive value; RT-PCR, reverse transcriptase-polymerase reaction; IgM, immunoglobulin
M; IgG, Immunoglobulin G; ELISA, enzyme-linked immunosorbent assay.
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ssays  have  improved  sensibility  and  speciﬁcity  as  shown  in
able  1.71 The  use  of  rapid  tests  is  not  recommended.  The
econd  sample  for  serological  determination  should  be  taken
etween  1  and  2  weeks  after  the  ﬁrst  sample.  Seroconver-
ion  can  also  be  detected  as  an  increase  in  IgG  by  a  factor
f  4  or  more  between  acute-phase  and  convalescent-phase
erum  samples.69
reatment
here  is  no  speciﬁc  antiviral  drug  treatment  for  CHIKV
nfection.  Symptomatic  treatment  is  recommended  after
xcluding  more  serious  conditions  like  malaria,  dengue,  and
acterial  infections.20,21
In  acute  infection,  treatment  is  symptomatic  and  sup-
ortive,  comprised  of  rest  and  the  use  of  acetaminophen
o  relieve  fever  (<4  g/day).  The  use  of  ibuprofen,  naproxen,
r  another  non-steroidal  anti-inﬂammatory  agent  (NSAID)  to
elieve  the  arthritic  component  of  the  disease  can  be  used
hen  dengue  infection  is  discarded.60 In  patients  with  severe
oint  pains  that  are  not  relieved  by  NSAID,  tramadol  or  nar-
otics  (e.g.,  morphine)  can  be  advised.60,61 Patients  should
e  advised  to  drink  plenty  of  ﬂuids  to  replenish  ﬂuid  lost
rom  sweating,  vomiting,  and  other  insensible  losses.60,72
While  recovery  from  CHIK  is  the  expected  outcome,
onvalescence  can  be  prolonged  and  persistent  joint
ain  may  require  pain  management,  including  long-term
nti-inﬂammatory  therapy.  Speciﬁc  treatment  for  diffuse
ost-CHIKV  polyarthralgia  in  chronic  stage  consists  of  oral
r  topic  NSAIDs  plus  a  short  course  of  oral  corticotherapy  or
orticoid  injection  in  affected  joint.  Neuropathic  pain  can
reated  with  tricyclic  antidepressants,  antiepileptic  drugs  or
ramadol.73
Although  an  older  study  suggested  that  hydroxychloro-
uine  phosphate  offered  some  beneﬁt  in  arthralgia,74
osterior  studies  failed  to  conﬁrm  its  efﬁcacy.73,75,76
In  patients  with  refractory  joint  symptoms,  alternative
herapies  such  as  methotrexate  (MTX)  can  be  evaluated.  In
 retrospective  study  made  in  La  Réunion  Island,  54  out  of
2  patients  had  a  positive  clinical  response  when  treated
ith  MTX.73,77 When  MTX  is  contraindicated  or  ineffective,
mmune-modulating  biologic  agents  as  etanercept,  ritux-
mab,  or  tocilizumab  can  be  used.73
It  has  been  shown  that  patients  with  rheumatoid  arthri-
is  have  low  vitamin  D  levels  and  a  negative  correlation  with
isease  activity.78 Therefore,  reposition  of  vitamin  D  could
mprove  disease  severity.  In  a  study  made  in  India,  patients
ith  chronic  CHIKV-related  arthritis  were  treated  with  vita-
in  D  and  calcium  for  ﬁve  months  which  improved  joint  pain
nd  fatigue.79
In  addition  to  pharmacotherapy,  cases  with  arthralgia
nd  joint  stiffness  may  beneﬁt  from  a  program  of  grad-
ated  physiotherapy  in  acute  and  chronic  stages  of  the
isease.  Movement  and  mild  exercise  tend  to  improve  morn-
ng  stiffness  and  pain,  but  heavy  exercise  may  exacerbate
ymptoms.revention
ending  vaccine  development,  the  only  effective  preventive
easures  consist  of  individual  protection  against  mosquito
s
t
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ites  and  vector  control.  Control  of  both  adult  and  larval
osquito  populations  uses  the  same  model  as  for  dengue
nd  has  been  relatively  effective  in  many  countries  and
ettings.80 Mosquito  control  is  the  best  available  method
or  preventing  CHIKV  infection.  Breeding  sites  must  be
emoved,  destroyed,  frequently  emptied,  and  cleaned  or
reated  with  insecticides.3
For  protection,  clothing  which  minimizes  skin  exposure
o  the  day-biting  vectors  is  advised.  Repellents  can  be
pplied  to  exposed  skin  or  to  clothing  in  strict  accor-
ance  with  product  label  instructions.  Repellents  should
ontain  DEET  (N,N-diethyl-3-methylbenzamide),  IR3535  (3-
N-acetyl-N-butyl]-aminopropionic  acid  ethyl  ester)  or
caridin  (1-piperidinecarboxylic  acid,  2-(2-hydroxyethyl)-
-methylpropylester).  Mosquito  coils  or  other  insecticide
aporizers  may  also  reduce  indoor  biting.3
accines
here  is  currently  no  commercial  vaccine  for  CHIKV,
lthough  some  candidate  vaccines  have  been  tested  in
uman  beings.81,82
Several  technologies  have  been  used  to  develop  CHIK  vac-
ines,  including  inactivated  viral  vaccines,  live-attenuated
iruses,  alphavirus  chimeras,  recombinant  viral  vaccines,
onsensus-based  DNA  vaccines,  recombinant  subunit  vac-
ines  and  more  recently,  a  virus-like  particle  (VLP)  vaccine.
Two  vaccine  candidates  have  ﬁnished  phase  I  trials:  a
ive  recombinant  measles-virus-based  chikungunya  vaccine
nd  the  VRC-CHKVLP059-00-VP,  VLP  vaccine.  The  live  recom-
inant  measles-virus-based  chikungunya  vaccine  had  good
mmunogenicity,  even  in  the  presence  of  measles  immu-
ity,  was  safe,  and  had  a  generally  acceptable  tolerability
roﬁle.83 The  VLP  vaccine,  VRC-CHKVLP059-00-VP  was  also
mmunogenic,  safe,  and  well  tolerated.84
conomic burden
n  India,  the  chikungunya  epidemic  in  2006  imposed  heavy
pidemiological  burden  and  productivity  loss  to  the  commu-
ity.  National  burden  of  chikungunya  was  estimated  to  be
5,588  DALYs  lost  during  2006  epidemic.  Persistent  arthral-
ia  was  found  to  impose  heavy  burden,  accounting  for  69%
f  the  total  DALYs.  The  productivity  loss  in  terms  of  income
oregone  was  estimated  to  be  a  minimum  of  6  million
SD.85 Other  studies  made  in  India  reported  that  the  burden
or  Andhra  Pradesh  was  6600  DALYs  (cost:  US$12,400,000).
hile  the  burden  was  moderate,  costs  were  high  and  mostly
ut  of  pocket.86
A  study  made  with  military  policemen  at  La  Réunion  in
une  2006  reported  that  most  symptomatic  patients  (93.7%)
omplained  of  a  chronic  stage  of  the  disease,  which  is  char-
cterized  by  pains  in  joints  or  bones,  or  both,  although  the
nquiry  was  made  6  months  after  the  epidemic  peak.  Most
orking  adults  are  disabled  with  loss  of  mobility,  hand  dis-
bility,  and  depressive  reaction,  which  can  each  last  for
eeks  to  months  and  has  negative  consequences  in  health,
ocial  organization,  and  economy  in  epidemic  areas.87,88
With  these  antecedents,  if  the  outbreak  spreads
hroughout  Mexico,  the  infected  working  adults  will  be  inca-
acitated,  and  will  increase  the  economic  burden.
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Conclusion
The  arrival  of  CHIKV  to  America  will  be  a challenge  to  the
public  health  system  and  a  signiﬁcant  economic  burden.  The
probability  of  autochthonous  transmission  in  the  rest  of  Mex-
ico  and  USA  is  high  due  to  the  vector  ubiquity.  Economic
development  does  not  protect  countries  from  vector-borne
diseases;  modern  lifestyles  may  amplify  an  epidemic  through
travel,  population  aging,  and  production  of  solid  waste  that
can  shelter  Aedes  mosquitoes.
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